Repligen Corp DEF 14A: Executive Equity Awards Detailed
Ticker: RGEN · Form: DEF 14A · Filed: Apr 4, 2025 · CIK: 730272
| Field | Detail |
|---|---|
| Company | Repligen Corp (RGEN) |
| Form Type | DEF 14A |
| Filed Date | Apr 4, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, equity-awards, sec-filing
TL;DR
Repligen's DEF 14A shows exec equity awards, focusing on fair value changes for 2024 and year-end values.
AI Summary
Repligen Corp filed a DEF 14A on April 4, 2025, detailing executive compensation and equity awards. The filing includes information on the change in fair value of outstanding equity awards granted in prior years for Named Executive Officers (NEOs) during the period of January 1, 2024, to August 31, 2024. It also reports on the year-end fair value of equity awards granted in covered years for NEOs outstanding and unvested as of December 31, 2024.
Why It Matters
This filing provides transparency into how executive compensation is structured, particularly concerning equity awards, which can influence company performance and shareholder value.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of executive compensation and does not inherently present new financial risks.
Key Numbers
- 2024-01-01 to 2024-08-31 — Reporting Period for Equity Award Changes (Covers changes in fair value of equity awards granted in prior years for NEOs.)
- 2023-12-31 — Year-End Date (Used for reporting year-end fair value of equity awards granted in covered years for NEOs.)
Key Players & Entities
- Repligen Corp (company) — Filer
- Tony J. Hunt (person) — Named Executive Officer
FAQ
What is the primary purpose of this DEF 14A filing for Repligen Corp?
The primary purpose is to disclose information related to executive compensation, particularly equity awards, as required by SEC regulations.
Which specific period does the filing cover for changes in fair value of equity awards for Named Executive Officers (NEOs)?
The filing covers the period from January 1, 2024, to August 31, 2024, for changes in the fair value of outstanding equity awards granted in prior years to NEOs.
What information is provided regarding the year-end fair value of equity awards?
The filing provides the year-end fair value of equity awards granted in covered years that were outstanding and unvested as of December 31, 2023, and also as of December 31, 2024.
Who is identified as a Named Executive Officer in relation to the equity award data?
Tony J. Hunt is identified as a Named Executive Officer in relation to the equity award data presented in the filing.
What is the SIC code for Repligen Corp?
The Standard Industrial Classification (SIC) code for Repligen Corp is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 4, 2025 by Tony J. Hunt regarding REPLIGEN CORP (RGEN).